Commerzbank Aktiengesellschaft FI Takes Position in Royalty Pharma PLC $RPRX

Commerzbank Aktiengesellschaft FI bought a new stake in Royalty Pharma PLC (NASDAQ:RPRX) during the fourth quarter, HoldingsChannel reports. The firm bought 25,417 shares of the biopharmaceutical company’s stock, valued at approximately $982,000.

A number of other hedge funds and other institutional investors have also modified their holdings of RPRX. Smartleaf Asset Management LLC increased its position in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares during the last quarter. Private Trust Co. NA increased its position in shares of Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 288 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 306 shares during the last quarter. Richardson Financial Services Inc. acquired a new stake in shares of Royalty Pharma in the third quarter valued at about $54,000. Finally, Fifth Third Bancorp increased its position in shares of Royalty Pharma by 16.9% in the third quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 362 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insiders Place Their Bets

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the transaction, the director owned 191,803 shares of the company’s stock, valued at $10,165,559. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.06, for a total value of $726,073.04. Following the transaction, the executive vice president directly owned 31,881 shares in the company, valued at approximately $1,691,605.86. This trade represents a 30.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 155,893 shares of company stock valued at $7,512,360 over the last 90 days. 18.84% of the stock is currently owned by insiders.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $52.85 on Friday. The business’s 50 day moving average price is $48.31 and its two-hundred day moving average price is $43.35. The company has a market cap of $30.43 billion, a PE ratio of 35.95, a price-to-earnings-growth ratio of 1.45 and a beta of 0.40. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a twelve month low of $32.15 and a twelve month high of $53.47.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The firm had revenue of $631.00 million for the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. On average, analysts predict that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Friday, May 15th. Royalty Pharma’s payout ratio is 63.95%.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. JPMorgan Chase & Co. lifted their target price on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Morgan Stanley lifted their target price on Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $53.71.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.